S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.46
+1.78
+10.67%
SNTI · Senti Biosciences Holdings, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Senti Biosciences Inc (SNTI)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.22
-0.00
(-1.74%)
● At close: October 20 at 4:00:00 PM EDT
DAY'S RANGE
$0.22
$0.21
$0.23
52-WEEK RANGE
$0.22
$0.21
$2.88
What's happening
- SNTI is down 1.74% today, trading at $0.22. — Live quote
- It's trading within 3% of its 52-week low ($0.21). (Finnhub fundamentals)
- Volume today (5,223) is well below its 3-month average of 707,170. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.41 actual vs. $-0.27 estimated (-51.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SNTI
-78.11%
vs S&P 500
-90.88%
1-YEAR RETURN
SNTI
-89.36%
vs S&P 500
-103.92%
6-MONTH RETURN
SNTI
-76.32%
3-MONTH RETURN
SNTI
-50.54%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.41
Est. $-0.27
MISS -51.7%
2026-04-26 (Q1 2026)
$-0.36
Est. $-0.37
BEAT +2.0%
2026-01-26 (Q4 2025)
$-0.53
Est. $-0.42
MISS -26.0%
2025-10-26 (Q3 2025)
$-0.69
Est. $-0.58
MISS -19.4%
Valuation Measures & Ratios
Enterprise Value4$4.6M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)128.94
Price / Book79.86
EV4 / Revenue84.03
EV4 / EBITDA—
Profit Margin-57160.00%
Operating Margin-68620.00%
Return on Equity (ROE8)-503.79%
Return on Assets (ROA9)-113.12%
Avg Volume (3M)707,170
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $33.7M | $24.5M | $37.0M | $57.6M | $32.6M |
| P/E | -0.68 | -0.48 | -0.49 | -0.84 | -0.49 |
| Price/Book | -9.92 | 9.55 | 4.56 | 2.34 | 0.86 |
| ROE | 1465.16% | -1995.79% | -933.84% | -279.55% | -175.10% |
| ROA | -150.52% | -133.87% | -143.94% | -100.55% | -80.08% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short487,169
Change from Prior Settlement-4.63%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -47.8% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -57160.0%. Finnhub fundamentals ↗
- Trailing 52-week price return is -89.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SNTI
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.0K | $16.0K | — | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$14.5M | -$4.6M | -$16.9M | -$16.8M | -$16.4M | -$15.2M | -$13.4M | -$16.3M |
| Net income | -$12.8M | -$4.2M | -$18.1M | -$14.7M | -$14.1M | -$28.9M | -$11.2M | -$12.1M |
| EPS (diluted) | $-0.41 | $-0.14 | $-0.69 | $-0.56 | $-1.41 | $-6.31 | $-2.45 | $-2.65 |
| EPS (basic) | $-0.41 | $-0.14 | $-0.69 | $-0.56 | $-1.41 | $-6.31 | $-2.45 | $-2.65 |
| Operating margin | -$85.2K | -$28.9K | — | — | — | — | — | — |
| Net margin | -$75.0K | -$26.4K | — | — | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $33.1M | $38.2M | $51.2M | $52.7M | $68.5M | $82.8M | $97.8M | $57.7M |
| Total liabilities | $36.5M | $35.7M | $45.6M | $44.6M | $43.9M | $44.9M | $47.1M | $41.7M |
| Stockholders' equity | -$3.4M | $2.6M | $5.6M | $8.1M | $24.7M | $37.9M | $25.6M | $16.0M |
| Total current assets | $13.0M | $14.8M | $23.3M | $18.2M | $32.5M | $45.2M | $59.0M | $17.4M |
| Total current liabilities | $15.8M | $14.3M | $14.0M | $12.0M | $10.0M | $10.7M | $13.1M | $9.1M |
| Cash & equivalents | $6.5M | $8.9M | $16.4M | $12.2M | $21.6M | $33.8M | $48.3M | $10.5M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | $288.0K | — | $0 | $0 | $0 | $0 | $584.0K | $8.0K |
| Property, plant & equipment | $11.4M | $12.1M | $12.9M | $18.7M | $19.6M | $20.5M | $21.3M | $22.2M |
| Other non-current assets | $0 | $5.0K | $19.0K | $34.0K | $52.0K | $76.0K | $105.0K | $88.0K |
| Accounts payable | $2.2M | $1.1M | $2.9M | $1.8M | $1.0M | $1.6M | $1.5M | $793.0K |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | $11.0K | $27.0K | $43.0K | — | — | — | $0 | — |
| Other non-current liabilities | $8.0M | $8.2M | $8.1M | $7.6M | $7.6M | $6.6M | $5.0M | $2.5M |
| Common stock & paid-in capital | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $1.0K | $1.0K |
| Retained earnings | -$375.5M | -$362.8M | -$358.6M | -$344.1M | -$326.0M | -$311.2M | -$297.1M | -$296.5M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.2M | -$7.5M | -$6.9M | -$9.4M | -$13.1M | -$14.1M | -$13.5M | -$7.9M |
| Investing cash flow | $0 | $114.0K | $0 | $0 | -$184.0K | $0 | -$11.0K | $60.0K |
| Financing cash flow | $9.7M | -$118.0K | $11.0M | $124.0K | $1.0M | -$414.0K | $51.3M | $2.4M |
| Free cash flow | -$14.2M | — | -$6.9M | -$9.4M | -$13.3M | -$14.1M | -$13.5M | -$7.9M |
| Capital expenditures | $0 | — | $0 | $0 | $196.0K | $0 | $11.0K | $0 |
| Share-based compensation | $1.0M | $1.3M | $1.4M | $1.6M | $1.5M | $1.2M | $605.0K | $668.0K |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | $1.2M | -$1.9M | $1.2M | $750.0K | -$537.0K | $357.0K | $1.2M | -$388.0K |
| Tax withholding on stock comp | $0 | $118.0K | — | — | $0 | $0 | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $22.0K | $0 | $2.0M | $3.3M | $2.3M |
| Operating income | -$68.8M | -$61.0M | -$92.7M | -$62.1M | -$40.4M |
| Net income | -$61.4M | -$52.8M | -$71.1M | -$58.2M | -$55.3M |
| EPS (diluted) | $-2.73 | $-12.03 | $-16.01 | $-2.23 | $-19.00 |
| EPS (basic) | $-2.73 | $-12.03 | $-16.01 | $-2.23 | $-19.00 |
| Operating margin | -$312.6K | — | -$4.7K | -$1.9K | -$1.8K |
| Net margin | -$279.3K | — | -$3.6K | -$1.8K | -$2.4K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $51.2M | $97.8M | $119.5M | $180.8M | $96.7M |
| Total liabilities | $45.6M | $47.1M | $52.6M | $53.5M | $36.3M |
| Stockholders' equity | $5.6M | $25.6M | $66.9M | $127.3M | -$111.5M |
| Total current assets | $23.3M | $59.0M | $71.2M | $102.6M | $60.2M |
| Total current liabilities | $14.0M | $13.1M | $12.7M | $18.1M | $14.5M |
| Cash & equivalents | $16.4M | $48.3M | $35.9M | $57.6M | $56.0M |
| Marketable securities (current) | — | — | $0 | $40.9M | $0 |
| Accounts receivable | — | — | — | $626.0K | $483.0K |
| Other current assets | $0 | $584.0K | $195.0K | $101.0K | $275.0K |
| Property, plant & equipment | $12.9M | $21.3M | $25.3M | $51.4M | $12.4M |
| Other non-current assets | $19.0K | $105.0K | $215.0K | $283.0K | $176.0K |
| Accounts payable | $2.9M | $1.5M | $1.2M | $1.4M | $5.2M |
| Accrued liabilities | — | — | — | — | $3.1M |
| Deferred revenue (current) | $43.0K | $0 | $0 | $799.0K | $1.7M |
| Other non-current liabilities | $8.1M | $5.0M | $0 | — | — |
| Common stock & paid-in capital | $3.0K | $1.0K | $1.0K | $4.0K | $0 |
| Retained earnings | -$358.6M | -$297.1M | -$244.3M | -$173.3M | -$115.1M |
| Accumulated other comprehensive income (loss) | — | — | $0 | $1.0K | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$43.4M | -$41.4M | -$52.4M | -$34.9M | -$34.6M |
| Investing cash flow | -$184.0K | $34.0K | $30.1M | -$82.0M | -$5.5M |
| Financing cash flow | $11.8M | $53.7M | $779.0K | $118.6M | $68.4M |
| Free cash flow | -$43.6M | -$41.4M | -$64.4M | -$76.3M | -$40.2M |
| Capital expenditures | $196.0K | $26.0K | $12.0M | $41.4M | $5.5M |
| Share-based compensation | $5.7M | $1.8M | $9.7M | $16.4M | $2.3M |
| Change in accounts receivable | — | — | — | $131.0K | $395.0K |
| Change in accounts payable | $1.7M | $797.0K | -$290.0K | $186.0K | -$617.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SNTI as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-02-04 to 2026-03-09
Recent transactions
- Most recent: Rajangam Kanya (Pres. & Chief Med. & Dev. Off.) — Tax withholding of 10,757 shares on 2026-03-09.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Tax withholding | 2026-03-09 | 10,757 |
| Lu Timothy K | CEO | Tax withholding | 2026-03-09 | 80,666 |
| Celadon Partners SPV 24 | 10% owner | Derivative conversion | 2025-03-10 | 9,777,000 |
| New Enterprise Associates 15, L.P. | Reporting person | Derivative conversion | 2025-03-10 | 3,333,000 |
| BAYER HEALTHCARE LLC | 10% owner | Derivative conversion | 2025-03-10 | 2,222,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-03-09 | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Tax withholding | 10,757 | $0.00 |
| 2026-03-09 | Lu Timothy K | CEO | Tax withholding | 80,666 | $0.00 |
| 2026-02-02 | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Tax withholding | 1,384 | $0.00 |
| 2026-02-02 | Lu Timothy K | CEO | Tax withholding | 4,191 | $0.00 |
| 2025-03-10 | Celadon Partners SPV 24 | 10% owner | Derivative conversion | 9,777,000 | — |
| 2025-03-10 | New Enterprise Associates 15, L.P. | Reporting person | Derivative conversion | 3,333,000 | — |
| 2025-03-10 | BAYER HEALTHCARE LLC | 10% owner | Derivative conversion | 2,222,000 | — |
| 2025-03-10 | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Derivative conversion | 33,000 | $2.25 |
| 2025-03-07 | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Grant / award | 78,363 | $0.00 |
| 2025-03-07 | Lu Timothy K | CEO and Interim PFO and PAO | Grant / award | 642,358 | $0.00 |
| 2025-02-06 | Lu Timothy K | CEO | Open market sale | 545 | $4.36 |
| 2025-02-04 | Lu Timothy K | CEO | Open market sale | 3,922 | $4.07 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:40 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-10-13 | 8-K | 2026-10-08 | View on SEC.gov → |
| 2026-09-24 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-09-04 | 8-K | 2026-09-03 | View on SEC.gov → |
| 2026-09-02 | 8-K | 2026-08-27 | View on SEC.gov → |
| 2026-08-20 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-15 | 8-K | 2026-07-14 | View on SEC.gov → |
| 2026-05-26 | 8-K | 2026-05-20 | View on SEC.gov → |
| 2026-05-14 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-14 | View on SEC.gov → |
| 2026-05-01 | 8-K | 2026-04-27 | View on SEC.gov → |
Recent news
Headlines about SNTI (Senti Biosciences Holdings, Inc.). Links open the publisher — we don’t host full articles.
-
Senti Biosciences (SNTI) Slides 11.63% to $0.23 as Sub-$1 Biotech Faces Renewed Pressure - Fibonacci Fan
https://www.siam.in/ · 2026-10-16 -
Which of Senti Biosciences (NASDAQ:SNTI), Autolus Therapeutics (NASDAQ:AUTL), Scinai Immunotherapeutics (NASDAQ:SCNI), Estrella Immunopharma (NASDAQ:ESLA) or Shuttle Pharmaceuticals (NASDAQ:SHPH) Is the Weakest Biotech o
kalkine.ca · 2026-10-16 -
Which of KALA BIO (NASDAQ:KALA), Senti Biosciences (NASDAQ:SNTI), Concorde International Group (NASDAQ:CIGL), Huachen AI Parking Management Technology (NASDAQ:HCAI) or Youlife Group (NASDAQ:YOUL) Trades Between 15 and 30
kalkine.ca · 2026-10-16 -
$Senti Biosciences (SNTI.US)$ building support
Moomoo · 2026-10-15 -
Senti Biosciences to spin off its gene-circuit pipeline
Seeking Alpha · 2026-07-15 -
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
Yahoo Finance · 2026-07-15 -
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Yahoo Finance · 2026-05-14 -
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
Yahoo Finance · 2026-05-14
No headlines in this category right now — try “All”.